- Home
- USEA vs PHIO Comparison
USEA vs PHIO Comparison
Compare USEA & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | USEA | PHIO |
|---|---|---|
| Founded | 2004 | 2011 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.2M | 12.5M |
| IPO Year | 2022 | 2011 |
Fundamental Metrics
Financial Performance| Metric | USEA | PHIO |
|---|---|---|
| Price | $2.08 | $1.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.67 |
| AVG Volume (30 Days) | 116.0K | ★ 7.2M |
| Earning Date | 01-01-0001 | 06-17-2026 |
| Dividend Yield | ★ 6.13% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.00 | $0.81 |
| 52 Week High | $2.28 | $4.19 |
Technical Indicators
Market Signals| Indicator | USEA | PHIO |
|---|---|---|
| Relative Strength Index (RSI) | 57.45 | 55.76 |
| Support Level | $1.63 | $1.01 |
| Resistance Level | $2.25 | $1.43 |
| Average True Range (ATR) | 0.12 | 0.09 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 54.65 | 94.49 |
Price Performance
Historical ComparisonAbout USEA United Maritime Corporation
United Maritime Corp is an international shipping company. It is engaged in seaborne transportation services. The group currently operates a fleet of five dry bulk vessels, comprising two Kamsarmax and three Panamax vessels with an aggregate cargo-carrying capacity of approximately 396,297 dwt.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.